PriceTargets.com logo

Veracyte - VCYT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $46.14
  • Forecasted Upside: 20.26%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$38.37 As of 02/2/2026 10:36 AM ET
▼ -0.37 (-0.96%)

This chart shows the closing price for VCYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veracyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCYT

Analyst Price Target is $46.14
▲ +20.26% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $46.14, with a high forecast of $50.00 and a low forecast of $43.00. The average price target represents a 20.26% upside from the last price of $38.37.

This chart shows the closing price for VCYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Veracyte. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/13/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
1/12/2026UBS GroupReiterated RatingBuy ➝ Buy
1/5/2026GuggenheimBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/1/2025Morgan StanleyBoost TargetUnderweight ➝ Underweight$40.00 ➝ $48.00
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/25/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/19/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/13/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/11/2025Morgan StanleyBoost TargetUnderweight ➝ Underweight$28.00 ➝ $40.00
11/7/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C)
11/5/2025UBS GroupBoost TargetBuy ➝ Buy$42.00 ➝ $48.00
11/5/2025Needham & Company LLCBoost TargetBuy ➝ Buy$41.00 ➝ $44.00
11/5/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$40.00 ➝ $43.00
11/5/2025GuggenheimBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
10/20/2025Canaccord Genuity GroupInitiated CoverageHold$40.00
10/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
10/6/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
8/8/2025Morgan StanleySet TargetUnderweight ➝ Underweight$28.00
5/8/2025UBS GroupLower TargetBuy ➝ Buy$49.00 ➝ $42.00
5/8/2025Needham & Company LLCLower TargetBuy ➝ Buy$51.00 ➝ $41.00
4/9/2025GuggenheimLower TargetBuy ➝ Buy$45.00 ➝ $37.00
3/26/2025StephensReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
3/20/2025Craig HallumInitiated CoverageBuy$45.00
2/25/2025GuggenheimReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
2/25/2025UBS GroupBoost TargetBuy ➝ Buy$46.00 ➝ $49.00
2/25/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
1/29/2025Needham & Company LLCBoost TargetBuy ➝ Buy$44.00 ➝ $51.00
12/5/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$38.00 ➝ $37.00
11/18/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$26.00 ➝ $28.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$50.00
11/8/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$40.00 ➝ $44.00
11/7/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$34.00 ➝ $38.00
11/7/2024UBS GroupBoost TargetBuy ➝ Buy$43.00 ➝ $46.00
11/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$37.00 ➝ $44.00
10/17/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
10/16/2024UBS GroupInitiated CoverageBuy$43.00
10/10/2024GuggenheimInitiated CoverageBuy$40.00
8/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$31.00 ➝ $37.00
8/12/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$21.00 ➝ $26.00
8/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$27.00 ➝ $31.00
5/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$33.00 ➝ $27.00
4/15/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$32.00 ➝ $28.00
2/26/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$22.00 ➝ $21.00
2/23/2024William BlairReiterated RatingOutperform
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $33.00
11/10/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$23.00 ➝ $22.00
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $30.00
11/8/2023William BlairReiterated RatingOutperform
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$37.00 ➝ $32.00
10/10/2023StephensReiterated RatingOverweight ➝ Overweight$34.00
8/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$34.00 ➝ $35.00
8/9/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$22.00 ➝ $23.00
2/23/2023Needham & Company LLCBoost TargetBuy$33.00 ➝ $34.00
1/18/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform
1/4/2023ScotiabankInitiated CoverageSector Outperform$33.00
11/4/2022Morgan StanleyLower TargetUnderweight$23.00 ➝ $22.00
11/4/2022Raymond James FinancialLower TargetOutperform$31.00 ➝ $27.00
11/3/2022Leerink PartnersBoost TargetOutperform$30.00 ➝ $35.00
11/3/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $33.00
11/2/2022William BlairReiterated RatingOutperform
8/4/2022Raymond James FinancialBoost TargetOutperform$30.00 ➝ $31.00
8/3/2022Needham & Company LLCBoost TargetBuy$26.00 ➝ $31.00
5/4/2022Needham & Company LLCLower Target$31.00 ➝ $26.00
3/15/2022Needham & Company LLCLower TargetBuy$35.00 ➝ $31.00
3/2/2022StephensLower TargetOverweight$52.00 ➝ $44.00
3/1/2022Lake Street CapitalLower Target$95.00 ➝ $50.00
3/1/2022Needham & Company LLCLower Target$55.00 ➝ $35.00
3/1/2022Raymond James FinancialLower TargetOutperform$62.00 ➝ $34.00
3/1/2022Leerink PartnersLower TargetOutperform$45.00 ➝ $40.00
1/7/2022StephensInitiated CoverageOverweight$52.00
11/18/2021The Goldman Sachs GroupInitiated CoverageBuy$59.00
11/10/2021William BlairReiterated RatingOutperform
11/10/2021Raymond James FinancialBoost TargetOutperform$50.00 ➝ $62.00
7/30/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $42.00
7/30/2021Needham & Company LLCBoost TargetBuy$54.00 ➝ $55.00
7/30/2021Leerink PartnersBoost TargetOutperform$55.00 ➝ $60.00
7/14/2021Leerink PartnersLower TargetOutperform$65.00 ➝ $55.00
6/28/2021Raymond James FinancialBoost TargetOutperform$45.00 ➝ $50.00
6/25/2021Needham & Company LLCReiterated RatingBuy
6/15/2021Raymond James FinancialInitiated CoverageOutperform$45.00
5/27/2021William BlairReiterated RatingBuy
5/18/2021Truist FinancialLower TargetBuy ➝ Buy$84.00 ➝ $55.00
5/12/2021Morgan StanleyLower TargetUnderweight$65.00 ➝ $45.00
5/11/2021Leerink PartnersLower TargetOutperform$75.00 ➝ $65.00
5/11/2021Needham & Company LLCLower TargetIn-Line ➝ Buy$88.00 ➝ $54.00
4/27/2021Leerink PartnersLower TargetOutperform$85.00 ➝ $75.00
4/14/2021Needham & Company LLCReiterated RatingBuy$88.00
2/25/2021Morgan StanleyBoost TargetUnderweight$35.00 ➝ $65.00
2/18/2021Leerink PartnersBoost TargetOutperform$83.00 ➝ $85.00
2/8/2021Leerink PartnersBoost TargetOutperform$40.00 ➝ $83.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 19 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 25 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
9/5/2025
  • 17 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 18 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 41 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 23 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2026
  • 11 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 11 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $38.37
Low: $37.33
High: $38.44

50 Day Range

MA: $43.35
Low: $38.08
High: $49.38

52 Week Range

Now: $38.37
Low: $22.61
High: $50.71

Volume

1,213,178 shs

Average Volume

761,357 shs

Market Capitalization

$3.03 billion

P/E Ratio

100.15

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Veracyte?

The following sell-side analysts have issued stock ratings on Veracyte in the last twelve months: Canaccord Genuity Group Inc., Craig Hallum, Guggenheim, Morgan Stanley, Needham & Company LLC, Stephens, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for VCYT.

What is the current price target for Veracyte?

0 Wall Street analysts have set twelve-month price targets for Veracyte in the last year. Their average twelve-month price target is $46.14, suggesting a possible upside of 21.2%. Guggenheim has the highest price target set, predicting VCYT will reach $50.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $43.00 for Veracyte in the next year.
View the latest price targets for VCYT.

What is the current consensus analyst rating for Veracyte?

Veracyte currently has 1 sell rating, 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VCYT, but not buy more shares or sell existing shares.
View the latest ratings for VCYT.

What other companies compete with Veracyte?

Other companies that are similar to Veracyte include Twist Bioscience, 10x Genomics, BrightSpring Health Services, Caris Life Sciences and Hims & Hers Health. Learn More about companies similar to Veracyte.

How do I contact Veracyte's investor relations team?

Veracyte's physical mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 243-6300 and its investor relations email address is [email protected]. The official website for Veracyte is www.veracyte.com. Learn More about contacing Veracyte investor relations.